- Home
- MIRA vs PRPO Comparison
MIRA vs PRPO Comparison
Compare MIRA & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRA
- PRPO
- Stock Information
- Founded
- MIRA 2020
- PRPO N/A
- Country
- MIRA United States
- PRPO United States
- Employees
- MIRA N/A
- PRPO 57
- Industry
- MIRA Biotechnology: Pharmaceutical Preparations
- PRPO Biotechnology: Laboratory Analytical Instruments
- Sector
- MIRA Health Care
- PRPO Industrials
- Exchange
- MIRA Nasdaq
- PRPO Nasdaq
- Market Cap
- MIRA 17.1M
- PRPO 9.5M
- IPO Year
- MIRA 2023
- PRPO N/A
- Fundamental
- Price
- MIRA $1.05
- PRPO $6.59
- Analyst Decision
- MIRA Strong Buy
- PRPO
- Analyst Count
- MIRA 2
- PRPO 0
- Target Price
- MIRA $14.00
- PRPO N/A
- AVG Volume (30 Days)
- MIRA 552.1K
- PRPO 7.9K
- Earning Date
- MIRA 11-11-2024
- PRPO 11-11-2024
- Dividend Yield
- MIRA N/A
- PRPO N/A
- EPS Growth
- MIRA N/A
- PRPO N/A
- EPS
- MIRA N/A
- PRPO N/A
- Revenue
- MIRA N/A
- PRPO $16,719,999.00
- Revenue This Year
- MIRA N/A
- PRPO $75.18
- Revenue Next Year
- MIRA N/A
- PRPO N/A
- P/E Ratio
- MIRA N/A
- PRPO N/A
- Revenue Growth
- MIRA N/A
- PRPO 52.61
- 52 Week Low
- MIRA $0.51
- PRPO $4.31
- 52 Week High
- MIRA $6.40
- PRPO $8.99
- Technical
- Relative Strength Index (RSI)
- MIRA 38.97
- PRPO 52.82
- Support Level
- MIRA $1.04
- PRPO $6.42
- Resistance Level
- MIRA $1.20
- PRPO $6.99
- Average True Range (ATR)
- MIRA 0.07
- PRPO 0.33
- MACD
- MIRA 0.02
- PRPO -0.04
- Stochastic Oscillator
- MIRA 19.44
- PRPO 69.91
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.